Skip to content
HowShorted

EAGLE PHARMACEUTICALS, INC. short interest in 2021

In 2021, EAGLE PHARMACEUTICALS, INC.'s disclosed short interest ran from 11.00% of shares outstanding on 15 Jan 2021 to 4.49% on 31 Dec 2021, a change of -6.51 percentage points. The year's high was 11.00% on 15 Jan 2021 and its low 4.49% on 31 Dec 2021, averaging 7.57% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.71 days on 28 May 2021. Full history: EAGLE PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024

Aggregate net short position time series for EAGLE PHARMACEUTICALS, INC. in 2021

2021 in figures

Start of year
11.00% (15 Jan 2021)
End of year
4.49% (31 Dec 2021)
Change
-6.51 pp
High
11.00% (15 Jan 2021)
Low
4.49% (31 Dec 2021)
Average
7.57%
Highest days to cover
14.71 (28 May 2021)
SEC filings marked
8

Every report in 2021

EAGLE PHARMACEUTICALS, INC. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202111.00%12.74
29 Jan 202110.73%14.25
12 Feb 20219.94%12.22
26 Feb 202110.77%13.72
15 Mar 202110.76%10.55results (8-K), 10-K filed
31 Mar 202110.48%13.55
15 Apr 20218.75%8.46
30 Apr 20218.08%13.83
14 May 20218.25%14.5910-Q filed, results (8-K)
28 May 20218.05%14.71
15 Jun 20217.86%7.29
30 Jun 20217.29%5.45
15 Jul 20217.06%7.16
30 Jul 20217.39%12.48
13 Aug 20217.03%11.5810-Q filed, results (8-K)
31 Aug 20216.56%6.85
15 Sep 20216.34%7.83
30 Sep 20216.04%6.69
15 Oct 20215.35%7.44
29 Oct 20215.26%9.86
15 Nov 20214.95%10.7910-Q filed, results (8-K)
30 Nov 20214.79%7.77
15 Dec 20214.53%3.83
31 Dec 20214.49%4.49

See also: EAGLE PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.